MX2010000937A - Tratamiento del trastorno por estrés postraumático. - Google Patents

Tratamiento del trastorno por estrés postraumático.

Info

Publication number
MX2010000937A
MX2010000937A MX2010000937A MX2010000937A MX2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A
Authority
MX
Mexico
Prior art keywords
post
stress disorder
traumatic stress
patient
compound
Prior art date
Application number
MX2010000937A
Other languages
English (en)
Spanish (es)
Inventor
Tom Woiwode
Mark Moran
Original Assignee
Synosia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics Inc filed Critical Synosia Therapeutics Inc
Publication of MX2010000937A publication Critical patent/MX2010000937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2010000937A 2007-07-23 2008-07-23 Tratamiento del trastorno por estrés postraumático. MX2010000937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93503607P 2007-07-23 2007-07-23
PCT/US2008/070948 WO2009015248A1 (en) 2007-07-23 2008-07-23 Treatment of post-traumatic stress disorder

Publications (1)

Publication Number Publication Date
MX2010000937A true MX2010000937A (es) 2010-06-25

Family

ID=40281815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000937A MX2010000937A (es) 2007-07-23 2008-07-23 Tratamiento del trastorno por estrés postraumático.

Country Status (12)

Country Link
US (1) US20090054403A1 (enExample)
EP (1) EP2182952A4 (enExample)
JP (1) JP2010534676A (enExample)
CN (1) CN101951912A (enExample)
AU (1) AU2008279091A1 (enExample)
CA (1) CA2707858A1 (enExample)
CO (1) CO6260078A2 (enExample)
MX (1) MX2010000937A (enExample)
NZ (1) NZ583193A (enExample)
RU (1) RU2458691C2 (enExample)
SG (1) SG183069A1 (enExample)
WO (1) WO2009015248A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015236A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
AU2016208412A1 (en) * 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
MX391921B (es) * 2007-08-06 2025-03-21 Biotie Therapies Inc Nepicastat para usarse en el tratamiento de dependencia
WO2011062614A1 (en) * 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
HRP20200055T1 (hr) 2013-03-15 2020-04-03 Tonix Pharma Holdings Limited Eutektičke formulacije ciklobenzaprin-klorovodika i manitola
JP6364488B2 (ja) * 2013-11-26 2018-07-25 ユニバーシティー オブ ノース テキサス ヘルス サイエンス センター アット フォートワースＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｔｅｘａｓ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅ Ｃｅｎｔｅｒ Ａｔ Ｆｏｒｔ Ｗｏｒｔｈ 認知欠損を治療するための個別化医療的手法
JP6614724B2 (ja) 2014-09-18 2019-12-04 トニックス ファーマ ホールディングス リミテッド シクロベンザプリン塩酸塩の共融製剤
RU2614697C1 (ru) * 2016-04-12 2017-03-28 Общество с ограниченной ответственностью "Нормофарм" Нейропротекторное средство
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
US10588890B2 (en) * 2017-05-30 2020-03-17 Biommunity, Inc. Compositions and methods to regulate hormonal cascades in stress disorders
US11284934B2 (en) * 2017-07-05 2022-03-29 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating sleep disorders in patients via renal neuromodulation
EP3720856A1 (en) 2017-12-04 2020-10-14 BIAL - PORTELA & Cª, S.A. Dopamine-& x392;-hydroxylase inhibitors
JP2021505629A (ja) 2017-12-11 2021-02-18 トニックス ファーマ ホールディングス リミテッド 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置
CN109966281B (zh) * 2019-04-11 2021-04-27 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用
US20220313647A1 (en) * 2019-07-25 2022-10-06 Tokyo University Of Science Foundation Agent for treating, preventing or improving psychiatric and nervous system disorders or symptoms
KR20250116086A (ko) * 2022-11-30 2025-07-31 블링크랩 리미티드 안검 추적을 이용한 정신약리학적 시스템 및 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1425017A1 (en) * 2001-09-13 2004-06-09 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
CA2483093A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
US20050209218A1 (en) * 2004-02-13 2005-09-22 Meyerson Laurence R Methods and compositions for the treatment of psychiatric conditions
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
EP1898915A4 (en) * 2005-07-06 2009-01-21 Sepracor Inc COMBINATIONS OF ESZOPICLON AND ANTIDEPRESSIVE
AU2008229203B2 (en) * 2007-03-16 2014-05-29 Emory University Methods and compositions for treatment of drug addiction
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder

Also Published As

Publication number Publication date
US20090054403A1 (en) 2009-02-26
CO6260078A2 (es) 2011-03-22
NZ583193A (en) 2012-05-25
RU2458691C2 (ru) 2012-08-20
WO2009015248A1 (en) 2009-01-29
CN101951912A (zh) 2011-01-19
JP2010534676A (ja) 2010-11-11
RU2010106014A (ru) 2011-08-27
CA2707858A1 (en) 2009-01-29
EP2182952A1 (en) 2010-05-12
SG183069A1 (en) 2012-08-30
EP2182952A4 (en) 2010-09-08
AU2008279091A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
MX2010000937A (es) Tratamiento del trastorno por estrés postraumático.
MX353727B (es) Tratamiento de sinucleinopatias.
MX2010006823A (es) Metodos para el tratamiento de la gota.
EA201001771A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
MA33043B1 (fr) Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie
WO2013033657A3 (en) CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY
MX391921B (es) Nepicastat para usarse en el tratamiento de dependencia
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
NZ600858A (en) Suture line administration technique using botulinum toxins
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
MX2009008135A (es) Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.
MX2011012666A (es) Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares.
MX2010000938A (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
IN2012DN00549A (enExample)
WO2006113900A3 (en) Methods and devices for relieving stress
EP2566502A4 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
NZ597115A (en) Method of treating age related disorders with fujimycin
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
WO2009152430A3 (en) Methods of treatment of bipolar disorder
WO2009036768A3 (en) Diagnosing potential weight gain in a subject

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIOTIE THERAPIES, INC.*

FA Abandonment or withdrawal